Advisers recommend improved labeling for phenytoin, fosphenytoin.
Kate
K
Traynor
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004348:Drug Labeling; D006801:Humans; D007231:Infant, Newborn; D010672:Phenytoin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D010672:Phenytoin; C043114:fosphenytoin